Cargando…

KRAS biomarker testing disparities in colorectal cancer patients in New Mexico

INTRODUCTION: American Society of Clinical Oncology (ASCO) guidelines recommend that all patients with metastatic colorectal cancer (mCRC) receive KRAS testing to guide anti-EGFR monoclonal antibody treatment. The aim of this study was to assess for disparities in KRAS testing and mutational status....

Descripción completa

Detalles Bibliográficos
Autores principales:	Greenbaum, Alissa, Wiggins, Charles, Meisner, Angela LW, Rojo, Manuel, Kinney, Anita Y, Rajput, Ashwani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701808/ https://www.ncbi.nlm.nih.gov/pubmed/29202108 http://dx.doi.org/10.1016/j.heliyon.2017.e00448

Ejemplares similares

Colorectal Cancer Incidence and Mortality Disparities in New Mexico
por: Hoffman, Richard M., et al.
Publicado: (2014)

RON kinase isoforms demonstrate variable cell motility in normal cells
por: Greenbaum, Alissa, et al.
Publicado: (2016)

Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
por: Yokota, Tomoya
Publicado: (2012)

The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
por: Tria, Simon Manuel, et al.
Publicado: (2023)

Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer
por: Ntavatzikos, Anastasios, et al.
Publicado: (2017)

Mechanisms of Immunosuppression in Colorectal Cancer
por: Zhang, Yang, et al.
Publicado: (2020)

Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology
por: László, Loretta, et al.
Publicado: (2021)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
por: Renaud, S, et al.
Publicado: (2015)

Therapeutic Targets of KRAS in Colorectal Cancer
por: Rahman, Shafia, et al.
Publicado: (2021)

Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories
por: Feigelson, Heather Spencer, et al.
Publicado: (2012)

Novel Approach for Clinical Validation of the cobas KRAS Mutation Test in Advanced Colorectal Cancer
por: Sharma, Abha, et al.
Publicado: (2016)

SUVmax and metabolic tumor volume: surrogate image biomarkers of KRAS mutation status in colorectal cancer
por: Lv, Ying, et al.
Publicado: (2019)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Impact of KRAS Mutations on Management of Colorectal Carcinoma
por: Sullivan, Kevin M., et al.
Publicado: (2011)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014)

KRAS Transitions and Villous Growth in Colorectal Adenomas
por: Risio, Mauro, et al.
Publicado: (2005)

KRAS-associated microRNAs in colorectal cancer
por: Ibrahim, Hamizah, et al.
Publicado: (2020)

KRAS mutations in patients with colorectal cancer in Libya
por: Abudabous, Asma, et al.
Publicado: (2021)

Disparities in Early-Onset Colorectal Cancer
por: Muller, Charles, et al.
Publicado: (2021)

KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment
por: Normanno, Nicola, et al.
Publicado: (2011)

Establishment and Validation of an Orthotopic Metastatic Mouse Model of Colorectal Cancer
por: Rajput, Ashwani, et al.
Publicado: (2013)

Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer
por: Eilertsen, Ina A., et al.
Publicado: (2018)

KRAS mutational analysis for colorectal cancer: Application: Pharmacogenomic
por: Wang, Grace, et al.
Publicado: (2010)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
por: Arrington, Amanda K., et al.
Publicado: (2012)

Novel KRAS Gene Mutations in Sporadic Colorectal Cancer
por: Naser, Walid M., et al.
Publicado: (2014)

Personalized treatment for advanced colorectal cancer: KRAS and beyond
por: Patel, Gargi Surendra, et al.
Publicado: (2013)

IMPACT OF KRAS MUTATIONS IN CLINICAL FEATURES IN COLORECTAL CANCER
por: ZANATTO, Renato Morato, et al.
Publicado: (2020)

Prognostic Value of KRAS Mutations in Colorectal Cancer Patients
por: Koulouridi, Asimina, et al.
Publicado: (2022)

Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer
por: NAKAMOTO, KENTARO, et al.
Publicado: (2013)

One-carbon metabolism biomarkers and genetic variants in relation to colorectal cancer risk by KRAS and BRAF mutation status
por: Myte, Robin, et al.
Publicado: (2018)

KRAS Early Testing: Consensus Initiative and Cost-Effectiveness Evaluation for Metastatic Colorectal Patients in an Italian Setting
por: Barone, Carlo, et al.
Publicado: (2014)

Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer
por: Kristensen, Lasse Sommer, et al.
Publicado: (2012)

Mapping the KRAS proteoform landscape in colorectal cancer identifies truncated KRAS4B that decreases MAPK signaling
por: Adams, Lauren M., et al.
Publicado: (2022)

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
por: Guedes, Joana G, et al.
Publicado: (2013)

Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS
por: Liu, Jiang, et al.
Publicado: (2016)

Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS
por: Lou, Emil, et al.
Publicado: (2021)

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_l45q34vjdokun7vlp43vrpv5k7